Therapeutic Strategies for LAM
While there is currently no cure for LAM, research has led to major progress in understanding and diagnosing LAM, including the identification of the genetic basis of the disease and a blood test that may assist with the diagnosis ( VEGF-D). These research efforts have prompted subsequent studies, including the first large-scale controlled clinical trial for women with LAM, which was supported by the National Institutes of Health and The LAM Foundation.
Sirolimus (rapamycin) - FDA Approved for LAM
Sirolimus blocks mammalian target of rapamycin (mTOR) signaling pathway that is dysregulated in LAM cells and lead to their proliferation. The use of sirolimus therapy may be considered in patients with moderate to severe LAM or those with progressive disease (See above MILES trial).
ADVERSE EFFECTS INFORMATION
Oral Ulceration with Sirolimus:
Sonis, S., Treister, N., Chawla, S., Demetri, G. and Haluska, F. (2010), Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer, 116: 210–215. doi: 10.1002/cncr.24696 - CLICK HERE
de Oliveira MA et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol (2011),
Pilotte, Amy Potter, Melissa Beth Hohos, Kathleen M. O. Polson, Tarsha Marie Huftalen, and Nathaniel Treister. 2011. “Managing Stomatitis in Patients Treated with Mammalian Target of Rapamycin Inhibitors.” Clinical Journal of Oncology Nursing 15 (5): E83–89. doi:10.1188/11.CJON.E83-E89. - CLICK HERE
Boers-Doets, Christine B., Judith E. Raber-Durlacher, Nathaniel S. Treister, Joel B. Epstein, Anniek B. P. Arends, Diede R. Wiersma, Rajesh V. Lalla, Richard M. Logan, Nielka P. van Erp, and Hans Gelderblom. 2013. “Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis.” Future Oncology (London, England) 9 (12): 1883–92. doi:10.2217/fon.13.141. - CLICK HERE
GnRH agonists (e.g. Lupron) have been used in patients with LAM, but benefits are unproven and induction of early menopause is distressing and morbid in young women.
Oophorectomy is no longer recommended in LAM patients. The procedure is invasive without clear evidence of efficacy.
Patients should be advised that pregnancy has been reported to result in exacerbations of LAM and pneumothorax. However, the risk of pregnancy in LAM has not been rigorously studied. Physicians and patients should discuss the risks of pregnancy carefully and decisions should be made on an individual basis.
Oxygen therapy may become necessary as the disease progresses,lung function becomes severely impaired, and hypoxemia is limiting. Based on extrapolation from the COPD populations, the use of oxygen may prolong life in hypoxic patients with LAM. Oxygen should be administered to maintain arterial oxygen saturations of 88-89% percent or greater with rest, exercise and sleep. Oxygen Supplementation will enhance exercise ability and distance and provide a more restful sleep. It can also help stabilize pulmonary hypertension. Newer and lighter weight oxygen systems allow for easier and more long distance travel.
More than 65 percent of patients with LAM develop pneumothorax and the average number of pneumothoraces per LAM patient is 3.5. The use of a pleurodesis procedure is recommended on the first pneumothorax, given the more than 70 percent chance of recurrence. Chemical pleurodesis (preferably with talc), mechanical abrasion, talc poudrage and pleurectomy have all been effective in patients with LAM.
Management of Renal Angiomyolipomas
Although most renal angiomyolipomas are asymptomatic, larger tumors (>4cm) may cause pain and bleeding. Transcatheter embolization therapy is usually preferred in the management of symptomatic renal angiomyolipomas. Renal-sparing surgical resection of tumors is another option.